ArticleThe Journal of endocrinology2018
Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.
Article in The Journal of endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Pseudocannabinoid H4CBD improves glucose response during advanced metabolic syndrome in OLETF rats independent of increase in insulin signaling proteins.American journal of physiology. Regulatory, integrative and comparative physiology · 2024Article
- Angiotensin receptor blockade with olmesartan alleviates brain pathology in obese OLETF rats.Clinical and experimental pharmacology & physiology · 2023Article
- Hemoglobin A1c and Angiographic Severity with Coronary Artery Disease: A Cross-Sectional Study.International journal of general medicine · 2022Article
- Role of stilbenes against insulin resistance: A review.Food science & nutrition · 2021Review
- Chronic ATAmerican journal of physiology. Endocrinology and metabolism · 2021Article
- Article
- Activation of ATBritish journal of pharmacology · 2020Article
- Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking.Environmental toxicology and pharmacology · 2020Review
- Partial Body Mass Recovery After Caloric Restriction Abolishes Improved Glucose Tolerance in Obese, Insulin Resistant Rats.Frontiers in endocrinology · 2020Article
- Mice lacking angiotensin type 2 receptor exhibit a sex-specific attenuation of insulin sensitivity.Molecular and cellular endocrinology · 2019Article
- Pancreatic AT1aR Deficiency Decreases Insulin Secretion in Obese C57BL/6 Mice.American journal of hypertension · 2019Article
- Angiotensin receptor and tumor necrosis factor-α activation contributes to glucose intolerance independent of systolic blood pressure in obese rats.American journal of physiology. Renal physiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Obesity is associated with the inappropriate activation of the renin-angiotensin system (RAS), which increases arterial pressure, impairs insulin secretion and decreases peripheral tissue insulin sensitivity. RAS blockade reverses these detriments; however, it is not clear whether the disease state of the organism and treatment duration determine the beneficial effects of RAS inhibition on insulin secretion and insulin sensitivity. Therefore, the objective of this study was to compare the benefits of acute vs chronic angiotensin receptor type 1 (AT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.